In vivo microdialysis evidence for central serotonin1A and serotonin1B autoreceptor blocking properties of the beta adrenoceptor antagonist (- )penbutolol

S Hjorth and T Sharp

Department of Pharmacology, University of Goteborg, Sweden.

Recently, we found that the beta 1/beta 2 adrenoceptor blocking agent (- )penbutolol prevents behavioral and biochemical actions of the specific serotonin (5-HT)1A agonist (+/-)-8-hydroxy-2-(di-n- propylamino)tetralin. The putative 5-HT1 receptor antagonist profile of (-)penbutolol was further explored in the present study, using in vivo microdialysis methods to assess its effects on central 5-HT release. (+)Penbutolol and (-)pindolol were included for comparison purposes. In contrast to (-)pindolol (8.0 mg/kg s.c.), administration of (- )penbutolol (2.0 or 8.0 mg/kg s.c.) increased hippocampal 5-HT output. The (-)penbutolol-induced 5-HT response was dose-related, stereoselective and Ca(++)-dependent. In addition, the 5-HT response to (-)penbutolol was abolished by omitting the 5-HT reuptake blocker citalopram from the perfusion medium, suggesting the need for endogenous 5-HT tone. Local (-)penbutolol (1 microM) perfusion increased the 5-HT output per se, and also blocked 5-HT release suppression caused by the 5-HT1B receptor agonist CP-93,129. Furthermore, (-)penbutolol, but not its (+)antipode, prevented the decrease of 5-HT release induced by the 5-HT1A receptor agonist (+/-)-8- hydroxy-2-(di-n-propylamino)tetralin. By comparison, the 5-HT1 receptor inactive beta adrenoceptor blockers metoprolol (beta 1) and ICI 118,551 (beta 2), given alone or in combination, did not increase 5-HT output and were ineffective in antagonizing the (+/-)-8-hydroxy-2-(di-n- propylamino)tetralin response. The data indicate that (-)penbutolol possesses 5-HT1A and 5-HT1B autoreceptor antagonist properties, and may be a useful tool in studies of central 5-HT receptor-mediated function.

Volume 265, Issue 2, pp. 707-712, 05/01/1993
Copyright © 1993 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				R. Tao, Z. Ma, and S. B. Auerbach Differential Effect of Local Infusion of Serotonin Reuptake Inhibitors in the Raphe versus Forebrain and the Role of Depolarization-Induced Release in Increased Extracellular Serotonin J. Pharmacol. Exp. Ther., August 1, 2000; 294(2): 571 - 579. [Abstract] [Full Text]

				G. Pineyro and P. Blier Autoregulation of Serotonin Neurons: Role in Antidepressant Drug Action Pharmacol. Rev., September 1, 1999; 51(3): 533 - 591. [Abstract] [Full Text] [PDF]

				A. Balcioglu and R. J. Wurtman Dexfenfluramine Enhances Striatal Dopamine Release in Conscious Rats via a Serotoninergic Mechanism J. Pharmacol. Exp. Ther., March 1, 1998; 284(3): 991 - 997. [Abstract] [Full Text]

				M. S. Kleven and W. Koek Discriminative Stimulus Effects of 8-Hydroxy-2-(di-n-propylamino)tetralin in Pigeons and Rats: Species Similarities and Differences J. Pharmacol. Exp. Ther., January 1, 1998; 284(1): 238 - 249. [Abstract] [Full Text]

				C. Gundlah, K. F. Martin, D. J. Heal, and S. B. Auerbach In Vivo Criteria To Differentiate Monoamine Reuptake Inhibitors from Releasing Agents: Sibutramine Is a Reuptake Inhibitor J. Pharmacol. Exp. Ther., November 1, 1997; 283(2): 581 - 591. [Abstract] [Full Text]

				M. J. Millan, S. Hjorth, R. Samanin, R. Schreiber, R. Jaffard, B. De Ladonchamps, S. Veiga, B. Goument, J.-L. Peglion, M. Spedding, et al. S 15535, A Novel Benzodioxopiperazine Ligand of Serotonin (5-HT)1A Receptors: II. Modulation of Hippocampal Serotonin Release in Relation to Potential Anxiolytic Properties J. Pharmacol. Exp. Ther., July 1, 1997; 282(1): 148 - 161. [Abstract] [Full Text]

				W. Kuipers, R. Link, P. J. Standaar, A. R. Stoit, I. Van Wijngaarden, R. Leurs, and A. P. Ijzerman Study of the Interaction Between Aryloxypropanolamines and Asn386 in Helix VII of the Human 5-Hydroxytryptamine1A Receptor Mol. Pharmacol., May 1, 1997; 51(5): 889 - 896. [Abstract] [Full Text]